Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. More Details
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Amphastar Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMPH is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: AMPH's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: AMPH underperformed the US Pharmaceuticals industry which returned 16.5% over the past year.
Return vs Market: AMPH underperformed the US Market which returned 34.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Amphastar Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StShareholders May Not Be So Generous With Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) CEO Compensation And Here's Why
2 months ago | Simply Wall StDid Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Insiders Sell Shares?
3 months ago | Simply Wall StDid You Miss Amphastar Pharmaceuticals' (NASDAQ:AMPH) 49% Share Price Gain?
Is Amphastar Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMPH ($21.5) is trading below our estimate of fair value ($129.84)
Significantly Below Fair Value: AMPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMPH is poor value based on its PE Ratio (407.7x) compared to the US Pharmaceuticals industry average (23.4x).
PE vs Market: AMPH is poor value based on its PE Ratio (407.7x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: AMPH is poor value based on its PEG Ratio (4.4x)
Price to Book Ratio
PB vs Industry: AMPH is good value based on its PB Ratio (2.5x) compared to the US Pharmaceuticals industry average (2.9x).
How is Amphastar Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMPH's forecast earnings growth (93.2% per year) is above the savings rate (2%).
Earnings vs Market: AMPH's earnings (93.2% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AMPH's revenue (10.2% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: AMPH's revenue (10.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMPH's Return on Equity is forecast to be high in 3 years time
How has Amphastar Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMPH has a large one-off loss of $22.1M impacting its March 31 2021 financial results.
Growing Profit Margin: AMPH's current net profit margins (0.7%) are lower than last year (15.9%).
Past Earnings Growth Analysis
Earnings Trend: AMPH's earnings have grown significantly by 21.4% per year over the past 5 years.
Accelerating Growth: AMPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AMPH had negative earnings growth (-95.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.9%).
Return on Equity
High ROE: AMPH's Return on Equity (0.3%) is considered low.
How is Amphastar Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AMPH's short term assets ($300.2M) exceed its short term liabilities ($127.1M).
Long Term Liabilities: AMPH's short term assets ($300.2M) exceed its long term liabilities ($67.7M).
Debt to Equity History and Analysis
Debt Level: AMPH's debt to equity ratio (9.8%) is considered satisfactory.
Reducing Debt: AMPH's debt to equity ratio has reduced from 13.6% to 9.8% over the past 5 years.
Debt Coverage: AMPH's debt is well covered by operating cash flow (178.7%).
Interest Coverage: AMPH earns more interest than it pays, so coverage of interest payments is not a concern.
What is Amphastar Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jack Zhang (74 yo)
Dr. Yongfeng Zhang, also known as Jack, Ph.D., serves as President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive ...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD5.96M) is above average for companies of similar size in the US market ($USD2.42M).
Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.
Experienced Management: AMPH's management team is seasoned and experienced (20.6 years average tenure).
Experienced Board: AMPH's board of directors are seasoned and experienced ( 17.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AMPH insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.
Amphastar Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Amphastar Pharmaceuticals, Inc.
- Ticker: AMPH
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.024b
- Shares outstanding: 47.64m
- Website: https://www.amphastar.com
Number of Employees
- Amphastar Pharmaceuticals, Inc.
- 11570 6th Street
- Rancho Cucamonga
- United States
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States,...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/03 23:41|
|End of Day Share Price||2021/08/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.